Was this the data GILD looked at when they purchas
Post# of 157795
(Total Views: 555)
Posted On: 01/30/2022 10:54:56 AM
Was this the data GILD looked at when they purchased IMMU ? Looks to be this is what they observed before they decided to merge/buyout IMMU for 21B.
https://www.nejm.org/doi/10.1056/NEJMoa1814213
It was a phase 1b/2 like us with slightly more people enrolled.
Will we have a published paper in NEJM? I don’t believe we have anything published there yet. Why ?
I rly want to see our data on TNBC. It sounds too good to be true that we will beat the SOC? Depending on our results alone we are worth more than the drug they purchased. Our trial was smaller but not by too much.
Yet we sit at .50. Does the market not trust the PR on TNBC? If they did we should be trading way higher or is the market waiting for more confirmation on these results. Like BTD from the FDA.
Thoughts ?
https://www.nejm.org/doi/10.1056/NEJMoa1814213
It was a phase 1b/2 like us with slightly more people enrolled.
Will we have a published paper in NEJM? I don’t believe we have anything published there yet. Why ?
I rly want to see our data on TNBC. It sounds too good to be true that we will beat the SOC? Depending on our results alone we are worth more than the drug they purchased. Our trial was smaller but not by too much.
Yet we sit at .50. Does the market not trust the PR on TNBC? If they did we should be trading way higher or is the market waiting for more confirmation on these results. Like BTD from the FDA.
Thoughts ?
(3)
(0)CytoDyn Inc (CYDY) Stock Research Links
Daniel Rizzo
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™
Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )
Website: FireGateBiotech.com
(For official updates and correspondence — I will no longer be posting here or responding via DMs)
Contact FireGate Biotech
Principal Investigator:
FG001|FG002|FG003
https://firegatebiotech.com/2025
FG-001: Integrated Triplet Immunotherapy for Functional HIV Cure
FG-002: Triplet Immunologic Modulation in Oncology — NF-κB / IL-1Ra Axis
FG-003: Neuro-Immune Repair Triplet — Concept and Combination Framework
CCR5 Antagonists & Triplet Immunotherapy Synergy in HIV
HIV Cure Pathways — Functional-Cure Framework Overview
FG-003 Neuro-Immune Repair Triplet — IP & Combination Strategy
— Jeremiah 51:36
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™
Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )
Website: FireGateBiotech.com
(For official updates and correspondence — I will no longer be posting here or responding via DMs)
Contact FireGate Biotech
Principal Investigator:
FG001|FG002|FG003
https://firegatebiotech.com/2025
FG-001: Integrated Triplet Immunotherapy for Functional HIV Cure
FG-002: Triplet Immunologic Modulation in Oncology — NF-κB / IL-1Ra Axis
FG-003: Neuro-Immune Repair Triplet — Concept and Combination Framework
CCR5 Antagonists & Triplet Immunotherapy Synergy in HIV
HIV Cure Pathways — Functional-Cure Framework Overview
FG-003 Neuro-Immune Repair Triplet — IP & Combination Strategy
— Jeremiah 51:36